Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company’s lead investigational therapy LOS ANGELES, February 17, 2026- ...
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of ...
Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company’s lead investigational therapy Turn Therapeutics, Inc. (Nasdaq ...
Jewish cultural institutions must be strengthened, but we cannot ignore the enemies at the gates 4 minute read You can save this article by registering for free here. Or sign-in if you have an account ...
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; ...
(MENAFN- GlobeNewsWire - Nasdaq) Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results